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Abstract
Background—After ablation of Barrett’s esophagus (BE), the esophagus heals with 
neosquamous epithelium (NSE). Despite normal endoscopic appearance, NSE exhibits defective 
barrier function with similarities to defects noted in the distal esophageal epithelium in patients 
with gas-troesophageal reflux disease (GERD).
Aim—To determine whether patients with NSE, unlike patients with healthy esophageal 
epithelium, have C-terminal fragments (CTFs) of e-cad detectable on tissue biopsy. Secondly, to 
determine whether patients with NSE have elevated levels of N-terminal fragments (NTFs) of e-
cad in the serum.
Methods—Fifteen patients with ablated long-segment BE, who had healing with formation of 
NSE, were enrolled in this pilot study. Western blots for CTFs and NTFs were performed on 
biopsies of NSE. Venous blood was obtained to assess levels of NTFs. Endoscopic distal 
esophageal biopsies from patients without esophageal disease served as tissue controls. Control 
blood samples were obtained from healthy subjects.
Results—Blots of NSE were successful in 14/15 patients, and all 14 (100 %) had a 35-kD CTF 
of e-cad, while CTFs were absent in healthy control tissues. Despite CTFs in NSE, serum NTFs of 
e-cad in NSE were similar to controls, p > 0.05. However, unlike healthy controls, blots of NSE 
also showed NTFs with molecular weights of 70–90 kD.
Conclusions—Cleavage of e-cad, as evidenced by the presence of CTFs and NTFs on biopsy, 
contributes to defective barrier function in NSE. However, unlike findings reported in GERD 
patients, serum NTFs are not elevated in NSE patients. This difference may reflect poor absorption 
with tissue entrapment of NTFs in previously ablated areas with poorly perfused NSE.
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Introduction
Barrett’s esophagus (BE) represents the presence of specialized columnar epithelium lining 
the distal esophagus [1–3]. BE is present in roughly 5–15 % of patients with 
gastroesophageal reflux disease (GERD), with GERD being the most recognized risk factor 
for its development [4–7]. Although BE is more acid-resistant than native esophageal 
squamous epithelium (ESE), it is a premalignant lesion, with an estimated risk of esophageal 
adenocarcinoma (EAC) of 0.1–0.5 %/year [8–10].
Radiofrequency ablation (RFA) is a common tool used to ablate dysplastic Barrett’s 
epithelium [11–15]. This technique, when combined with continuous acid suppressive 
therapy using proton-pump inhibitors (PPIs), results in healing of the ablated segments with 
a new stratified squamous epithelium called “neosquamous epithelium (NSE)” to distinguish 
it from native ESE [13, 16]. NSE is not just a by-product of ablation therapy, but an essential 
component for its success in preventing recurrence of BE. Moreover, a stable NSE also 
serves to prevent exposure of any submucosal islands of Barrett’s to acidic refluxate, which 
may in turn forestall the evolution from metaplasia to EAC [13]. The durability of NSE as 
replacement for BE, however, is at best uncertain as evidenced by the reported rates of 
recurrence of BE following ablation. For instance, recurrence of BE following successful 
ablation by RFA has been reported in 6–25 % of patients within 1 year [11, 15, 17–19], 
while recurrence of BE has been reported to occur following ablation by argon plasma 
coagulation (APC) in up to 66 % of patients within 15 months [20–23].
Concern about the durability of NSE has been underscored previously by our laboratory. We 
have observed that NSE exhibits features of defective barrier function, defects which persist 
in NSE for ≥2 years following ablation despite proton-pump inhibitor (PPI) therapy [16]. 
Specifically, NSE morphologically exhibits dilated intercellular spaces, and this in 
combination functionally with low transepithelial electrical resistance (RT) and high 
mucosal-to-serosal fluorescein flux indicates increased paracellular permeability [24–27]. 
Notably, these structural and functional changes are similar to those previously documented 
in the acid reflux-damaged ESE in patients with GERD. This suggests that NSE and reflux-
damaged ESE in GERD may share other similarities with respect to their observed increases 
in paracellular permeability. Cleavage of the junctional protein e-cadherin is a specific defect 
that, in GERD, contributes to increased paracellular permeability [27]. Consequently, we 
hypothesized that like the reflux-damaged ESE in GERD, cleavage of e-cadherin would also 
be demonstrable in NSE. To test this hypothesis, we performed a pilot study to determine 
whether, like the ESE in GERD, cleavage of e-cadherin was evident in NSE by the presence 
of carboxy-terminal fragments (CTFs) of e-cad-herin in biopsies of NSE and/or there were 
increased levels of aminoterminal fragments (NTFs) of e-cadherin present in serum of 
patients with NSE.
Methods
Patient Population
We performed a prospective cohort study of adult patients, aged 18–75, who presented to the 
University of North Carolina (UNC) for endoscopic follow-up ≥3 months following RFA of 
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BE. All subjects had baseline BE of ≥3 cm in length. All were taking daily PPI therapy, and 
all had on endoscopy complete healing of the ablated segment with NSE. Endoscopic 
biopsies were obtained from the area of NSE and placed in RNA-Later for determination of 
CTFs by Western blot. After 24 h in RNA-Later, the fixative was removed and the tissue 
stored at −80 °C until use. A peripheral venous blood sample was also obtained at the time 
of endoscopy and after allowing time to clot, it was spun down and serum decanted into 
vials and stored at −80 °C until use for the determination of NTFs of e-cadherin by ELISA.
Controls were adult patients, aged 18–75, who presented to UNC for diagnostic upper 
endoscopy and who had no history of esophageal symptoms such as heartburn, dysphagia, 
regurgitation, or odynophagia and no signs of esophageal abnormality on endoscopy. 
Esophageal biopsies were obtained from the distal 3–5 cm of esophagus and handled as for 
patients with NSE for Western blot analysis. Additionally, to compare serum NTFs by 
ELISA, serum samples were purchased from Innovative Research (Novi, MI) of healthy 
adult subjects that were race- and sex-matched to those of NSE patients. This study was 
approved by the University of North Carolina Institutional Review Board.
CTFs and NTFs of E-cadherin in Esophageal Biopsies
Western blots were performed on biopsies of NSE and from healthy ESE of controls to 
determine the presence of CTFs and NTFs of e-cadherin within the epithelia. The C-
terminus of the linear e-cadherin protein is intracellular, while the N-terminus of e-cadherin 
resides in the extracellular space. Consequently, to identify CTFs remaining within the 
epithelial cells following cleavage, a C-terminal antibody is used. In contrast, to identify 
soluble N-terminal fragments of e-cadherin which following cleavage are released into the 
intercellular space where they potentially can be picked up by the capillary circulation, an 
N-terminal antibody is used (see ELISA below). The primary antibodies used for tissue were 
either against CTFs of human e-cadherin (Catalog# 33-4000, Zymed Laboratories, San 
Francisco, CA) or against NTFs of human e-cadherin (Catalog# 13-1700, Invitrogen, 
Camarilla, CA). Secondary antibodies were goat anti-mouse, IRDye 800 (Catalog# 
610-132-121, Rockland, Gilbertsville, PA). For detection of actin (loading controls) on 
Western blots, we used a rabbit primary antibody (Catalog #A2066, Sigma, St. Louis) and 
goat anti-rabbit secondary antibody (Catalog# 611-130-122, Rockland, Gilbertsville, PA). 
Signals on the blot were detected using an Odyssey Infrared Imaging System (LI-COR, Inc., 
Lincoln, NE). Since e-cadherin has a molecular weight of 120 kD, CTFs or NTFs were 
recognized on Western blots as green bands with molecular weights smaller than 120 kD and 
quantitated with respect to actin (red bands) using densitometry by ImageJ analysis. The 
presence of significantly greater quantities of CTFs or NTFs on Western blots in 
neosquamous epithelium compared to controls was taken as evidence of cleavage of e-
cadherin in the tissue.
NTFs of E-Cadherin in Serum
For quantitation of NTFs of e-cadherin in serum, an enzyme-linked immunosorbent assay 
(ELISA) (kit obtained from Invitrogen, Carlsbad, CA) was performed for patients with NSE 
and for controls. Serum for NTFs from these two groups was run as a single batch to avoid 
variation introduced by technique. In brief, a monoclonal antibody specific for the 
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extracellular (N-terminus) domain of e-cadherin is coated onto microtiter plates. Samples 
containing an unknown amount of NTFs are incubated in the wells at 37 °C for 2 h. A 
second, detecting, monoclonal antibody (conjugated with peroxidase) is incubated in the 
wells at 37 °C for 1 h. Peroxidase substrate solution (H2O2 and tetramethylbenzidine) is 
added and results in a color change. The reaction is terminated by the addition of 1 M 
H2SO4 and absorbance of the sample measured using a microtiter plate reader at 450 nm. 
Each sample is measured twice and the average value used for determination of the NTFs of 
e-cadherin from a standard curve plotted using values obtained from standard solutions 
provided with the kit. Serum NTF levels from patients with NSE were compared to serum 
NTF levels from healthy subjects, and if elevated in NSE patients, this is taken as 
presumptive evidence for cleavage of e-cadherin.
Statistical Analysis
Descriptive statistics were used to summarize data, and bivariate analyses performed using 
Student’s t test. Student’s t test was used to compare mean serum NTFs in patients versus 
controls. The presence of CTFs and NTFs on Western blots for tissue samples was 
confirmed both qualitatively and quantitatively, the latter by densitometry performed in 
ImageJ and t test statistics calculated using Excel.
Results
Fifteen patients with endoscopically normal NSE and 7 endoscopic controls were enrolled in 
the study. The average age was 66 ± 6 years, and the subjects were predominantly male 
(93 % male) and all Caucasian (15/15). Slightly less than half (47 %) had GERD symptoms 
at the time of enrollment, and a mean of 144 ± 84 weeks had elapsed between the last RFA 
and study enrollment. The mean length of BE at endoscopy was 5.9 ± 2.2 cm. Two patients 
(13 %) were taking PPI once daily and the rest twice or more daily. Tissue controls were 
obtained from patients scheduled for endoscopy without esophageal symptoms or signs and 
biopsies obtained from grossly normal appearing distal (lower 5 cm) esophageal epithelium. 
Table 1 lists demographic and disease-specific characteristics of cases.
Western blots were performed on esophageal biopsies from all patients; however, the 
biopsies from 1 NSE patient were lost in processing so that results were available for 14 of 
15 patients. Using the antibody to the C-terminus of e-cadherin, biopsies of NSE from all 14 
patients and of native esophageal epithelium from all 7 controls had a prominent band at 120 
kD representing intact e-cadherin. CTF bands in controls were absent or faintly detectable 
on Western blots, while all 14 (100 %) of the Western blots of NSE showed one or more 
prominent bands compatible with CTFs of e-cadherin. This is illustrated in Fig. 1a by the 
presence on Western blot of one or more green bands with molecular weights less than 120 
kD, the most prominent being localized to a molecular weight of 35 kD. Further, as shown 
by densitometric analysis in Fig. 1c, quantitatively there were significantly more CTFs in 
neosquamous epithelium than in control tissues.
Western blots were also performed on esophageal biopsies from the 14 patients with NSE 
and from 3 controls using an antibody to the N-terminus of e-cadherin. Biopsies of NSE 
from all 14 patients and of native esophageal epithelium from the 3 controls had a prominent 
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band at 120 kD representing intact e-cadherin. No other NTF bands were identifiable on the 
Western blots of controls. However, 12 of 14 (85.7 %) of the Western blots of NSE showed 
bands compatible with NTFs of e-cadherin. This is illustrated in Fig. 2a by the presence on 
Western blot of green bands with molecular weight less than 120 kD—the bands being 
localized between molecular weights 70 and 90 kD. Further, as shown by densitometric 
analysis in Fig. 2c, quantitatively there are significantly more NTFs in neosquamous 
epithelium than in control tissues.
Quantification of serum NTFs by ELISA showed that the mean values for patients with NSE 
were similar to that of healthy controls, 67.7 ± 20 pg/ml versus 62.3 ± 19 pg/ ml, 
respectively, p = 0.56. There was also considerable overlap in values between groups, with 
NSE patients having a range of 41–104 pg/ml and controls 42–88 pg/ml (Fig. 3). Notably, 
there were two patients with NSE that underwent 24-h esophageal pH monitoring during the 
study period—with one, despite PPI therapy, being found to have elevated esophageal total 
acid contact time of 24.3 % and the other a normal esophageal total acid contact time of 
1.5 %. Interestingly, the NSE patient with high acid contact time had high serum NTFs (70.4 
pg/ml) and the NSE patient with normal acid contact time had low serum NTFs (42.7 pg/ml; 
Fig. 3).
Discussion
NSE, like the reflux-damaged distal esophageal epithelium in GERD patients, has defective 
barrier function. This is evident in both tissues morphologically by the presence of dilated 
intercellular spaces and functionally by a low RT and high mucosal-to-serosal fluorescein 
flux [16, 24–28]. These findings indicate that both NSE and the distal esophageal epithelium 
in GERD patients have an increase in paracellular permeability, i.e., a “leaky” route for ions 
and uncharged molecules between squamous epithelial cells. Recent studies in esophageal 
epithelium in GERD patients show that one reason for the “leaky” paracellular pathway is a 
defect in zonula adherens, as shown by the presence of CTFs of e-cadherin on esophageal 
biopsy and higher levels of NTFs of e-cadherin in serum of GERD patients [27]. In the 
esophageal epithelium from GERD patients, this cleavage appears to be related to the 
activation of “a disintegrin and metalloproteinase” (ADAM) within the squamous cell 
membranes, though the exact means for this activation remains unknown [27].
In the present study, we found that like the esophageal epithelium in GERD patients, NSE 
that arises in lower esophagus post-ablation of BE also exhibits evidence of high levels of 
active cleavage of e-cadherin. This was documented by the presence of increased levels of 
CTFs and NTFs of e-cadherin on Western blots of NSE, and the absence or very minimal 
presence of these fragments in Western blots of controls. The cleavage of e-cadherin in NSE, 
as in the esophageal epithelium in GERD patients, likely contributes to the “leakiness” of its 
paracellular pathway. This is because e-cadherin is the intercellular bridging protein for the 
zonula adherens, an essential junctional structure that completely encircles the squamous 
cells in stratum corneum. Moreover, the zonula adherens is located just below and supports 
the more luminally oriented tight junction which ultimately controls the diffusion of ions 
and uncharged molecules through the paracellular pathway [29–32]. Consequently, without 
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an intact zonula adherens, the integrity of the claudin-rich tight junctions is compromised 
and the paracellular pathway becomes more “leaky” [31, 33].
In this study, the cleavage of e-cadherin in NSE, as in the esophageal epithelium in GERD 
patients, was evident by the high levels of CTFs of e-cadherin with molecular weight of 35 
kD. A CTF of this size is consistent with cleavage of e-cadherin by activation of ADAM, an 
enzyme sheddase that cleaves at the cell membrane and releases soluble protein fractions 
[27, 34–36]. We have no direct evidence that activation of an ADAM in squamous cells is 
responsible for this component of cleavage of e-cadherin in NSE. However, given the 
similarities between NSE and the esophageal epithelium in GERD patients, we speculate 
that such activation and consequent cleavage of e-cadherin could be caused by exposure of 
NSE to refluxed gastric acid. However, in this study unfortunately this hypothesis could not 
be sufficiently tested as esophageal pH monitoring information was only available for one 
subject.
However, in contrast to our findings in patients with GERD, CTFs in patients with NSE 
were not associated with high levels of serum NTFs. The reason for this finding in our study 
is not clear. One possibility is that cleavage of e-cadherin occurs at lower rates in NSE than 
in GERD. Another explanation could be that cleaved NTFs are not able to reach the 
systemic circulation. RFA destroys the entire esophageal mucosa in treated areas and, in 
doing so, disturbs or destroys capillaries supplying blood to the area. Depending on the 
richness of reconstituted capillaries in NSE, soluble N-terminal fragments may have limited 
access to the systemic circulation. Evidence we present suggesting NTFs are detectable in 
tissue biopsies in NSE supports such a concept. In GERD, especially non-erosive GERD, 
capillary damage would not be expected to occur, and it is possible that NTFs can more 
easily access the systemic circulation in that milieu.
The importance of barrier function in NSE relates to its ability to serve a durable protective 
function against acid reflux injury, the latter being the initial cause for development of BE 
and presumptively for its recurrence following successful ablation. Indeed, the presence of a 
defective barrier would effectively lend itself to acid-induced damage to NSE by promoting 
acid access through the paracellular route to the basolateral membranes of squamous cells 
wherein lie the transport mechanisms that result in acid absorption and acidification of the 
cytosol of squamous cells [37]. That acid reflux plays a role in recurrence of BE following 
successful ablation is supported by the data of Kahaleh et al. [38], who found that 83 % of 
patients with recurrence of BE post-ablation by APC had pathologic acid exposure on 
esophageal pH monitoring compared to only 12.5 % of patients that had normal esophageal 
acid exposure. Moreover, the risk of acid reflux in patients with BE (and with NSE) is 
known to be problematic even when taking PPI therapy—with up to 50 % of BE patients 
continuing to experience pathologic acid reflux even while asymptomatic and on PPIs twice 
daily [39–41]. Taken together, these data suggest that greater attention needs to be paid to 
the health and integrity of NSE since its durability in part determines the post-ablation risk 
of BE recurrence—and by extrapolation, the need following ablation for continued 
endoscopic surveillance to identify recurrence of BE and repeat endoscopic treatments with 
RFA to avoid potential evolution from metaplasia to EAC. It is clearly better to take good 
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care of the NSE the first time around, than to have to recurrently destroy the epithelium due 
to recurrent BE.
There are several limitations to this pilot study. First, the numbers of NSE patients are small 
and so the lack of elevated levels of NTFs in NSE as seen in GERD could reflect a type 2 
error. However, given the lack of a suggestive trend in these data, this is unlikely. Second, 
the absence of esophageal pH probe studies limits our ability to document the role of acid 
reflux in the cleavage of e-cadherin. While such studies would be a welcome addition to this 
work, our past studies demonstrate that the addition of a pH study decreases patient 
willingness to participate. Third, what role the cleavage of e-cadherin plays in the recurrence 
of BE remains speculative. Whether this cleavage indicates the loss of a vital protective 
structure, or whether it is an inconsequential happenstance, or “innocent bystander,” and 
victim to ongoing acid damage is unclear. Nonetheless, we can conclude that the NSE that 
develops following RFA in patients with BE exhibits high levels of active cleavage of e-
cadherin and that such cleavage likely contributes to its defective barrier function. Such 
defective barrier function, we propose, increases the vulnerability of NSE to acid reflux 
damage and as such to the risk of recurrence of BE. Given the relatively high rate of 
recurrence of BE after initially successful RFA, larger studies are clearly merited to establish 
the validity of these concepts, and to address ways to better protect the NSE.
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CTFs C-terminal fragments
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ELISA Enzyme-linked immunosorbent assay
EAC Esophageal adenocarcinoma
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Fig. 1. 
a Western blot using antibodies to the C-terminal fragments (CTFs) of e-cadherin for 
esophageal biopsies illustrated from 3 healthy control subjects and 7 subjects with 
neosquamous epithelium [specimen of neosquamous epithelium in column 3 was lost in 
processing]. Note that green bands for intact e-cadherin with molecular weight (MW) 120 
kD are present in all 3 controls and all 7 with neosquamous epithelium. Small CTFs of e-
cadherin (green bands) with MW 35 kD are shown to be absent in controls and clearly 
present in 6 of 7 with neosquamous epithelium. The seventh neosquamous epithelium 
exhibits faint, but positive, staining for CTFs of e-cadherin. Actin staining (red band) is 
shown at 42 kD. b E-cadherin and c CTF levels were measured by densitometry and 
normalized to actin. Means of the control group (healthy individuals 1–3) and experiment 
group (biopsies with neosquamous epithelium 1, 2, 4–8; note that biopsy 2 could not be 
quantified due to an anomaly in the gel lane) were plotted and compared using the t test. The 
error bars represent standard error. N.S. not significant
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Fig. 2. 
a Western blot using antibodies to the N-terminal fragments (NTFs) of e-cadherin for 
esophageal biopsies from 3 healthy control subjects and 7 subjects with neosquamous 
epithelium [specimen of neosquamous epithelium in column 2 was lost in processing]. Note 
that green bands for intact e-cadherin with molecular weight (MW) 120 kD are present in all 
3 controls and all 7 with neosquamous epithelium. NTFs of e-cadherin with MWs ranging 
from 70 to 90 kD (green bands) are shown to be absent in controls and clearly present in 6 of 
7 with neosquamous epithelium. Actin staining (red bands) are shown at 42 kD. b E-
cadherin and c NTF levels were measured by densitometry and normalized to actin. Means 
of the control group (healthy individuals 1–3) and experiment group (biopsies with 
neosquamous epithelium 3–7; note that biopsies 1, 2, 8 could not be quantified due to 
anomalies in the gel lanes) were plotted and compared using the t test. The error bars 
represent standard error. N.S. not significant
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Fig. 3. 
Boxplot of serum NTF levels from patients with NSE compared to serum NTF levels from 
healthy controls. The lines within each box represent the median values of each group. 
Levels obtained using enzyme-linked immunosorbent assay of N-terminal fragments (NTFs) 
of e-cadherin in sera from patients with neosquamous epithelium (NSE) and healthy 
controls, p > 0.05. Note: Patient A had a pathologically high acid contact time on esophageal 
pH monitoring (24.3 %) in association with the high level of NTFs in serum (70.4 pg/mL) 
and patient B had a normal acid contact time on pH monitoring (1.5 %) in association with a 
normal level of NTFs (42.7 pg/mL) in serum
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Table 1
Demographic data of patients with neosquamous epithelium
Age, y, mean ± SD 66 ± 6
Male, n (%) 14 (93 %)
Caucasian race, n (%) 15 (100 %)
GERD symptoms at baseline*, n (%) 7 (54 %)
Length of BE, cm, mean ± SD 5.9 ± 2.2
Time elapsed since RFA, weeks, mean ± SD 144 ± 84
*Symptom history information not available for two patients
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